In 2018, the Pharma Services biologics business within Thermo Fisher Scientific, supported the commercialization of two new therapeutics for its clients. The St. Louis, Missouri and the Groningen, Netherlands sites both completed FDA Pre-Approval Inspections (PAIs) and received Establishment Inspection Reports (EIRs) for the commercial manufacture of biologic therapies.
In the spirit of providing life-changing biologics for patients, Thermo Fisher Pharma Services is proud to announce the expansion of its St. Louis, Missouri biologics facility. The expansion will increase the company’s capacity to advance medicines to meet patients’ needs. On September 21st, 2018, Thermo Fisher Scientific hosted a public dedication event with elected officials and over 400 employees to commemorate this significant addition.
Biopharmaceutical companies take on a lot of risk developing new large molecule drugs. With more complex molecules in development, changing capacity needs, uncertain forecasts and increased competition, the market demands flexibility and innovative approaches to address today’s new challenges.